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Abstract: Bone marrow-derived mesenchymal stromal cells (BM-MSCs) represent the 
leading candidate cell in tissue engineering and regenerative medicine. These cells can be 
easily isolated, expanded in vitro and are capable of providing significant functional 
benefits after implantation in the damaged muscle tissues. Despite their plasticity, the 
participation of BM-MSCs to new muscle fiber formation is controversial; in fact, 
emerging evidence indicates that their therapeutic effects occur without signs of long-term 
tissue engraftment and involve the paracrine secretion of cytokines and growth factors with 
multiple effects on the injured tissue, including modulation of inflammation and immune 
reaction, positive extracellular matrix (ECM) remodeling, angiogenesis and protection 
from apoptosis. Recently, a new role for BM-MSCs in the stimulation of muscle progenitor 
cells proliferation has been demonstrated, suggesting the potential ability of these cells to 
influence the fate of local stem cells and augment the endogenous mechanisms of 
repair/regeneration in the damaged tissues. 
Keywords: cell-based therapy; cell proliferation; mesenchymal stromal cells (MSCs); 
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1. Introduction 
Skeletal and cardiac muscles have received much attention in the last years with respect to their 
regenerative capacities. It is well known that adult skeletal muscle can efficiently undergo 
repair/regeneration in response to trauma or degenerative diseases due to the activity of a resident 
population of muscle progenitors, namely satellite cells [1]. These mononucleated cells are localized 
underneath the basal lamina of each muscle fiber closely juxtaposed to the sarcolemma, within special 
niches. Here, these cells lie in a dormant state and start to proliferate and differentiate in response to 
signals emanating from the damaged fibers and infiltrating inflammatory cells in order to form new 
myofibers within a few days [2?6]. Unfortunately, satellite cells are relatively scarce within the 
skeletal muscle tissue, representing about 1%?5% of the total muscle nuclei and, in the case of severe 
muscle damage, they might not be recruited in a sufficient amount at the site of tissue damage. 
Moreover, their capacity to accomplish the myogenic program is highly compromised by the induction 
of the inflammatory response and the excessive fibroblast proliferation and collagen fiber  
deposition [7?9]. Recently, a small population of resident stem/myogenic progenitors (cardiac stem 
cells, CSCs) have also been identified in the adult heart of mammals including humans, questioning 
the traditional paradigm of the myocardium as a post-mitotic terminally differentiated tissue [10?14]. 
These cells are mainly localized into sub-epicardial clusters in the atria, in the ventricular base through 
the midregion and in the apex [10,11] However, differently from satellite cells, resident CSCs are 
mainly involved in the maintenance of cardiac tissue homeostasis [15?17], showing a limited 
regenerative potential [18?21]. Many researchers have thus been devoted to the development of 
therapeutic strategies for the treatment of degenerative muscle diseases; among them, the stem  
cell-based therapy is emerging as one of the most promising tools in the field of regenerative  
medicine [6,20,22?27]. The most obvious candidate cells to be transplanted for skeletal muscle 
regeneration are the satellite cells, whose therapeutic potency has been demonstrated in experimental 
models of human dystrophy and skeletal muscle injury [22,28,29]. However, their use for regenerative 
purposes is hindered by several criticisms including: (i) the high heterogeneity of this cell  
population [30]; (ii) the loss of their myogenic potential upon isolation and in vitro expansion [29]; 
(iii) the predetermination dependent from the source (slow versus fast, head versus limb muscles) of 
skeletal muscle fibers [31,32]; (iv) the scarce cell survival in the host tissue [33]; and, (v) the inability 
to cross the blood vessel wall, restricting their use to the local injection [23]. The therapeutic 
application of CSCs in the injured myocardium has also some limitations and concerns substantially 
related to the absence of a full understanding of the biological and immunophenotypical features of 
these cells and to the difficulties of their culture expansion and implantation [12,34?39]. These hurdles 
have shifted the attention of many researchers in the field of cell-based therapy to other stem cell 
types, in particular to adult bone marrow-derived mesenchymal stromal cells (BM-MSCs) for the 
treatment of the damaged muscle. These cells, in fact, possess unique biological properties which 
render them promising candidate cells to be used in preclinical and clinical settings for tissue 
repair/regeneration.  
This concise review will focus on the therapeutic applications of BM-MSCs for skeletal and cardiac 
muscle repair /regeneration, paying particular attention to the mechanisms through which these cells 
exert their beneficial effects. 
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2. Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) 
2.1. Biological Properties 
MSCs constitute a rare population of adult stem cells, found in situ within all adult mammalian 
supportive stromal tissue compartments; however, their main source remains the bone marrow where 
they were first identified over 40 years ago [40,41]. These cells are defined on the basis of their plastic 
adherence in standard culture condition, a spindle-shaped appearance, their phenotypic characteristics 
and a capability to be induced to differentiate into adipocytes, osteoblasts and chondrocytes. The 
phenotype definition requires the expression of CD73 (an ecto-5'-nucleotidae, involved in bone 
marrow stromal interactions, MSC migration and modulation of adaptive immunity), CD90 (Thy1 
antigen, with unknown function) and CD105 (or endoglin, the transforming growth factor (TGF)-??
receptor III implicated in MSC chondrogenic differentiation) together with the lack of expression of 
CD11b and CD14 (monocyte and macrophage markers), CD34 (hematopoietic progenitor and 
endothelial cell marker), CD45 (leukocyte marker) CD19 or CD79a (B cell marker) and human 
leukocyte antigen (HLA)-DR surface molecules [42,43]. Despite these well-established criteria for 
defining MSCs, their isolation is hindered by the possible contamination of non-mesenchymal cells, 
resulting in a heterogeneous cell population with unpredictable MSC content [44]. Therefore, 
alternative preparation strategies have been recently postulated to improve the purity of the cell 
culture, such as the use of novel antibodies with specific reactivity against cell surface molecules 
highly expressed by MSCs (Stro-1, Stro-3, Stro-4, CD71, VCAM-1) [44,45]. MSCs possess many 
biological properties that make these cells ideal candidates for tissue engineering and regenerative 
medicine. These properties include: the ease of accessibility for isolation from the patients or bone 
marrow banks; the high expansion potential [46,47]; and, the presumptive plasticity, that is, being able 
to differentiate in vitro, not only into mesenchymal, but also non-mesenchymal lineages, including 
myoblasts [48], cardiomyocytes [49,50], hepatocyte-like cells [51], neuronal and neuroglial  
cells [52,53] and endothelial cells [54]. Moreover, when transplanted systemically, MSCs are able to 
migrate and home to the specific site of injury [55,56] and exert anti-inflammatory and 
immunosuppressive effects thus allowing a potential for their autologous and allogenic use [57?59]. 
Moreover, the absence of ethical issues concerning their tissue source and the lack of tumorigenicity 
represent additional advantages for their use in clinical applications [60,61]. 
2.2. Contribution of BM-MSCs to Muscle Repair/Regeneration 
A large body of experimental evidence has shown that transplantation of BM-MSCs in animal 
models of muscle injury and disease has great therapeutic potential [6,62]. Indeed, the systemic or 
local administration of BM-MSCs into skeletal muscles subjected to traumatic injuries such as 
laceration [63], crush [64?66] or cardiotoxin injection [67,68], have been demonstrated to contribute to 
myofiber formation and to the functional recovery of the muscle tissue. A considerable augment in the 
capillary density and collateral perfusion, associated with a reduction of myofiber atrophy and disarray 
has also been observed in ischemic skeletal muscles transplanted with BM-MSCs [69?71]. Moreover, 
some studies reported that the injection of BM-MSCs into dystrophic muscles is capable to restore 
dystrophin expression [67,72?74], attenuate the oxidative stress [75], and improve the motor  
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function [74]. Positive outcomes have been also obtained when BM-MSCs were utilized for treating 
post-myocardial infarction heart failure in both small (mouse and rat) and large animal (swine and dog) 
models. The administration of BM-MSCs (either by intravascular, intramyocardial or transendocardial 
injection), have in fact provided comprehensive functional benefits which include: attenuation of left 
ventricular negative remodelling with a reduction of the infarct size, increase of vascular density and 
myocardial perfusion [76?84], preservation of residual myocardium, and improvement of the 
contractile [76?78,81,85?88] and electrical properties [89,90]. However, despite these positive 
findings, there are controversies on the actual ability of BM-MSC to regenerate contracting myocardial 
tissue. Moreover, their retention and engraftment after transplantation into the diseased muscle still 
remain major limitations [76,77,91]. 
A number of clinical trials using autologous and allogenic BM-MSCs have been performed to 
improve the cardiac function in patients with acute myocardial infarction, or affected by chronic 
ischemic cardiomyopathy (Table 1). These studies have been proven to be generally safe and feasible 
without notable side effects; moreover, patients receiving BM-MSC therapy have experienced clinical 
benefits mainly in terms of scar reduction, a decrease in arrhythmias, an attenuation of ventricular 
contraction dysfunctions and an increase in left ventricular ejection fraction [92?99]. 
However, despite the encouraging outcomes, a deeper understanding of BM-MSC biology is 
required in order to validate their effective therapeutic benefits for muscle tissue repair/regeneration 
and elucidate the potential risks of their use in clinical applications. 
2.3. Trophic Actions 
There is a general consensus that the beneficial effects of BM-MSCs observed in animal models of 
human muscle disease, including acute and chronic myocardial infarction and dystrophy are mainly 
dependent on the trophic activity of the administered cells, rather than to their plasticity or stemness 
potential [100?104]. Many studies have shown, in fact, that MSCs do not differentiate into the cells of 
the injured organs and exert transient therapeutic effects in the absence of significant long-term 
engraftment (the injected cells are, in fact, rapidly lost after days from implantation) [105,106]. 
However, the implanted cells are metabolically and functionally active, capable of producing paracrine 
trophic factors with multiple effects in the host tissue microenvironment, including modulation of the 
endogenous repair mechanisms and prevention of injured cells from the stress response and  
apoptosis [106,107]. In this line, our group and others have shown that BM-MSCs produce, under 
normal culture conditions, a wide array of growth factors and cytokines [108,109] and can be activated 
to express and release higher levels of therapeutic factors in response to stress or inflammation  
signals [110,111]. While the administration of various single growth factors have demonstrated beneficial 
results in skeletal [112?115] and cardiac regeneration [116?119], the unique value of  
MSC-therapy resides in the possibility to obtain local, constant and biologically effective levels of different 
functionally synergistic trophic factors in the contest of the regenerating tissue and to achieve more 
sustained therapeutic effects. The best studied paracrine factors produced by BM-MSCs are those involved 
in the regulation of the innate immunity; accumulating evidence during the last years have, in fact, 
demonstrated that BM-MSCs have distinctive immunomodulatory and anti-inflammatory properties [58]. 
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Table 1. Clinical trials using BM-MSC therapy for cardiac repair/regeneration. 
Trial Name ClinicalTrials.gov 
Identifier 
Sponsor/ Collaborator Location Disease Source Route of 
Delivery 
Patients Status 
Prospective randomized study of 
mesenchymal stem cell therapy in patients 
undergoing cardiac surgery 
(PROMETHEUS) 
NCT00587990 National Heart, Lung, and Blood 
Institute (NHLBI) 
Johns Hopkins University Specialized 
Center for Cell Based Therapy  
USA Chronic ischemic left 
ventricular disfunction 
Autologous Intramyocardia
l injection 
45 Completed 
Stem cell injection to treat heart damage 
during open heart surgery 
NCT01557543 National Heart, Lung, and Blood 
Institute (NHLBI) 
USA Heart disease 
Ischemic heart disease 
Coronary artery disease  
Autologous Intramyocardia
l injection 
24 Recruiting 
Safety and efficacy of intracoronary adult 
human mesenchymal stem cells after acute 
myocardial infarction 
NCT01392105 Yonsei University 
FCB 
Pharmicell Co Ltd. 
Republic 
of Korea 
Acute myocardial 
infarction 
(AMI) 
Autologous Intracoronary 
injection 
80 Completed 
Stem cell therapy for vasculogenesis in 
patients with severe myocardial ischemia 
NCT00260338 Righospitalet, Copenhagen Denmark 
Jens Kastrup 
Denmark Myocardial ischemia 
Coronary heart disease 
Autologous Intramyocardia
l injection 
31 Completed  
Autologous mesenchymal stromal cell 
therapy in heart failure 
NCT00644410 Righospitalet, Copenhagen Denmark 
Jens Kastrup 
Denmark  Heart failure Autologous Intramyocardia
l injection 
60 Recruiting 
Prochymal® (human adult stem cells) 
intravenous infusion following acute 
myocardial infarction (AMI) 
NCT00877903 Osiris Therapeutics USA 
Canada 
Acute myocardial 
infarction 
(AMI) 
Allogenic Intravenous  
injection 
220 Active,  
not 
recruiting 
Safety Study of AMI MultiStem® to treat 
Heart attacks 
NCT00677222 Athersys, Inc 
PPD 
Angiotech Pharmaceuticals 
USA Acute myocardial 
infarction 
(AMI) 
Allogenic Via catheter into 
peri-vascular 
space injection 
25 Completed 
A phase II dose-escalation study to assess 
the feasibility and safety of transendocardial 
delivery of three different doses of 
allogeneic mesenchymal precursor cells 
(MPCs) in subjects with heart failure 
NCT00721045 Angioblast Systems, U.S. USA Heart failure Allogenic Trans-
endocardial 
injection 
60 Unknown  
(last verified 
June 2010: 
active, not 
recruiting) 
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This notion is remarkable, but not surprising; wide evidence, in fact, suggests that communication 
of BM-MSCs and cells of the immune system starts at the level of the bone marrow niche, where it 
play a crucial role in maintaining and preserving the undifferentiated state of the hematopoietic stem 
cells [41]. Recent in vivo and in vitro observations have demonstrated that the crosstalk between  
BM-MSCs and the innate immunity results from a combination of direct cell?cell contact and soluble 
factor-mediated mechanisms, including the release of molecules and bioactive metabolites with 
immunomodulatory action, such as interleukin (IL)-10, transforming growth factor (TGF)-?,  
galectin-1, galectin-3, leukemia inhibitory factor (LIF), nitric oxide and prostaglandin  
E2 (PGE2) [58]. A clear example of these interactions is the documented ability of BM-MSCs to 
mediate the transition of classically activated M1 macrophages into anti-inflammatory M2 
macrophages, which participate in tissue healing, promoting the resolution of inflammation and the 
clearance of apoptotic cells [120,121]. The crosstalk between BM-MSCs and macrophages is further 
highlighted by the findings showing that BM-MSCs can prevent the release of tumor necrosis factor 
(TNF)-? and other inflammatory chemokines from activated macrophages, through the secretion of 
IL-1 receptor antagonist (IL-1RA) [122], and stimulate monocytes to release IL-1?, thus enhancing 
MSC-mediated secretion of TGF-? and the subsequent T lymphocyte suppression [123]. Beyond the 
inhibition of macrophage function, BM-MSCs also sustain the survival and the suppressive phenotypes 
of T regulatory lymphocytes, interfere with differentiation of dendritic cells and B lymphocytes, and 
inhibit proliferation and functionality of natural killer (NK) cells [124]. All these findings, together 
with the observation that BM-MSCs are immunoprivileged cells, owing to the low expression levels of 
HLA major histocompatibility complex (MHC) class I and co-stimulatory molecules, have raised the 
clinical interest in these cells, exploiting the possibility of a universal donor of BM-MSCs for  
therapeutic applications. 
In addition to these effects, transplanted BM-MSCs may facilitate other complementary aspects of 
tissue repair, which, however, are considered prerequisites for tissue reconstitution and functional 
improvement and include augmentation of cell survival (limited apoptosis), promotion of angiogenesis 
and vasculogenesis, and inhibition of scarring (fibrosis). They are mediated in large part by a number 
of MSC-secreted factors which are capable of: (i) activating pro-survival pathways in the transplanted 
as well as resident viable cells ((IL-6 and IL-10, stromal cell-derived factor 1(SDF-1)) [125?128];  
(ii) stimulating blood vessel growth (VEGF, fibroblast growth factor (FGF), IL-1, matrix 
metalloproteinases (MMPs), platelet derived growth factor (PDGF), TGF-??????????????) [129,130]; (iii) 
promoting favourable extracellular matrix remodeling (IL-10) and altering the passive characteristics of 
the scar [131]; and, (iv) inhibiting fibroblast?myofibroblast transition and the following collagen 
synthesis and deposition (hepatocyte growth factor ?HGF, adrenomedullin) [132?134]. 
Interestingly, it has been recently shown that BM-MSCs might affect cardiac or skeletal muscle 
repair via cytokine-induced enhancement of the host tissue (endogenous) stem cell function [135?137]. 
In this context, we have demonstrated in co-culture systems that BM-MSCs enhance neonatal cardiac 
as well as C2C12 skeletal myoblast proliferation (Figure 1) through a combination of juxtacrine and 
paracrine mechanisms that involve the activation of Notch-1 signaling [108,109]. We have also shown 
that these effects were mainly mediated by the release of VEGF by BM-MSCs [109]. Consistent with 
these findings, in vivo experiments have shown that injection of BM-MSCs promote the activation of 
muscle satellite cells and the formation of new myofibers in the injected skeletal muscles [75]. 
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Moreover, the engrafted BM-MSCs can directly participate in the recruitment and differentiation of the 
endogenous cardiac progenitor cells in the diseased myocardium, via the paracrine release of SDF-????
a potent chemoattractant for stem cells [127,138]. 
Figure 1. Bone marrow-derived mesenchymal stromal cells (BM-MSCs) stimulate 
proliferation of muscle progenitor cells. Representative superimposed differential 
interference contrast (DIC) and confocal fluorescence images showing the pyrimidine 
analogue EdU (5-ethynyl-2'-deoxyuridine) staining (green) in the nuclei of proliferating 
murine C2C12 skeletal myoblasts or murine neonatal cardiomyocytes in single and  
co-culture for 24 h with mouse Dil-labeled BM-MSCs (red). Note the higher number of 
proliferating cells in the co-culture systems. 
 
 
2.4. Strategies to Advance the Therapeutic Properties of BM-MSCs 
Much emphasis is currently given to the identification of new strategies to optimize the cell fate 
after in vivo BM-MSC administration. These techniques target a wide array of biological functions, 
including the cell homing, survival, proliferation and paracrine secretion. Studies have shown that  
preconditioning by exposure to reduced levels of oxygen, incubation with nitric oxide, hydrogen 
peroxide or diazoxide, and treatment with pharmacological drugs, including phosphodiesterase 
inhibitors, angiotensin II receptor blocker and neuropeptide Y, may greatly enhance the therapeutic 
promise of BM-MSCs [44]. Moreover, it has been recently shown by our group that the treatment with 
platelet-derived rich plasma (PRP) [139], as well as irradiation with low level lasers [140], represent 
promising preconditioning approaches for stimulating BM-MSC proliferation, encompassing 
senescence during cell expansion and influencing stemness gene expression. Of interest, the genetic 
manipulation of MSC to overexpress cytokines and growth factors, such as HGF, VEGF and SDF-1, 
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have also been proposed to improve neo-angiogenesis and the endogenous mechanisms of tissue 
repair/regeneration [44,141,142]. Finally, bioengineered three-dimensional matrices have been shown 
to represent appropriate devices to preserve the survival of the engrafted MSCs and assist their 
migration within the damaged tissues [139,143,144].  
3. Conclusions and Future Perspectives 
BM-MSCs are considered among the best candidates for cell-based therapy for skeletal and cardiac 
muscle repair/regeneration. Their beneficial effects are mainly related to the release of a wide range of 
trophic factors with multiple effects in the host tissue (Scheme 1). Of particular interest are the 
findings showing that BM-MSCs stimulate proliferation and differentiation of the resident muscle 
progenitors, providing novel concepts for considering these cells as instructing and supporting 
elements capable of modulating the endogenous tissue repair mechanisms. In vitro priming of  
BM-MSCs by a wide variety of techniques may be used to complement the biological and biochemical 
properties of these cells and allow the expansion of their therapeutic potential. However, at present, the 
clinical application of BM-MSCs is considered with caution and long-term studies are still required in 
order to elucidate the side effects and validate the safety of these cells for tissue regeneration. 
Scheme 1. Therapeutic paracrine effects of bone marrow derived mesenchymal stromal 
cells (BM-MSCs) for skeletal and cardiac muscle repair/regeneration. Abbreviations: 
ECM: Extracellular matrix; FGF: Fibroblast growth factor; HGF: Hepatocyte growth 
factor; IL-1: Interleukin 1; IL 6: Interleukin-6; IL-10: Interleukin 10; MMPs: Matrix 
metalloproteinases; PDGF: Platelet derived growth factor; TGF-?: transforming growth 
factor-?; VEGF: Vascular endothelial growth factor; SDF-1: stromal derived factor-1;  
IL-1RA: interleukin 1 receptor antagonist; PGE2: prostaglandin E2; LIF: leukemia 
inhibitory factor; NO: Nitric oxide. 
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